Information  X 
Enter a valid email address

Company Name matching 'Ultimovacs ASA'

Date
Time Source
Company
Announcement
12 May 2022 7:00 am GNW   Ultimovacs ASA Ultimovacs ASA: First quarter 2022 result presentation
10 May 2022 7:00 am GNW   Ultimovacs ASA Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting
05 May 2022 7:00 am GNW   Ultimovacs ASA Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation
22 Apr 2022 7:00 am GNW   Ultimovacs ASA Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations
21 Apr 2022 3:30 pm GNW   Ultimovacs ASA Ultimovacs ASA - Share Option Program
  10:14 am GNW   Ultimovacs ASA Ultimovacs ASA – Annual General Meeting held on 21 April 2022
08 Apr 2022 6:00 pm GNW   Ultimovacs ASA Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development
  3:30 pm GNW   Ultimovacs ASA Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
30 Mar 2022 10:00 am GNW   Ultimovacs ASA Ultimovacs to host Investor Days 2022: Meet the Team
25 Mar 2022 7:47 am GNW   Ultimovacs ASA Correction: Ultimovacs ASA: Annual Report 2021
  6:50 am GNW   Ultimovacs ASA Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022
  6:30 am GNW   Ultimovacs ASA Ultimovacs ASA: Annual Report 2021
21 Mar 2022 7:00 am GNW   Ultimovacs ASA Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma
09 Mar 2022 3:30 pm GNW   Ultimovacs ASA Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting
17 Feb 2022 12:18 pm GNW   Ultimovacs ASA Ultimovacs ASA: Mandatory notification of trade by primary insider
  7:00 am GNW   Ultimovacs ASA Ultimovacs ASA: Fourth quarter 2021 result presentation
10 Feb 2022 7:00 am GNW   Ultimovacs ASA Ultimovacs ASA: Invitation to fourth quarter 2021 results webcast presentation
03 Feb 2022 7:00 am GNW   Ultimovacs ASA Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study
15 Dec 2021 7:00 am GNW   Ultimovacs ASA First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer
02 Dec 2021 6:00 pm GNW   Ultimovacs ASA Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma
  3:30 pm GNW   Ultimovacs ASA Ultimovacs ASA: Mandatory notification of trade by primary insider
29 Nov 2021 7:15 pm GNW   Ultimovacs ASA Ultimovacs ASA: Mandatory notification of trade by primary insider
25 Nov 2021 7:00 am GNW   Ultimovacs ASA Ultimovacs ASA: Mandatory notification for close associate
11 Nov 2021 7:00 am GNW   Ultimovacs ASA Ultimovacs ASA: Third quarter 2021 result presentation
09 Nov 2021 1:00 pm GNW   Ultimovacs ASA Ultimovacs’ SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma
03 Nov 2021 7:00 am GNW   Ultimovacs ASA Ultimovacs ASA: Invitation to third quarter 2021 results presentation
02 Nov 2021 9:57 am GNW   Ultimovacs ASA Ultimovacs ASA – New share capital registered
27 Oct 2021 6:37 am GNW   Ultimovacs ASA Ultimovacs ASA – Transactions by primary insiders and closely associated parties
26 Oct 2021 11:06 pm GNW   Ultimovacs ASA Ultimovacs ASA - Private placement of new shares successfully placed
  3:31 pm GNW   Ultimovacs ASA Ultimovacs ASA - Contemplated private placement
  3:30 pm GNW   Ultimovacs ASA Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)
21 Oct 2021 7:00 am GNW   Ultimovacs ASA Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma
15 Oct 2021 9:50 am GNW   Ultimovacs ASA Ultimovacs ASA: New share capital registered
13 Oct 2021 7:00 am GNW   Ultimovacs ASA Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma
12 Oct 2021 5:34 pm GNW   Ultimovacs ASA Ultimovacs ASA: Share capital increase related to exercise of options
08 Oct 2021 8:07 am GNW   Ultimovacs ASA Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances
01 Oct 2021 11:30 am GNW   Ultimovacs ASA Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
20 Aug 2021 7:00 am GNW   Ultimovacs ASA Ultimovacs ASA: Second quarter 2021 result presentation
12 Aug 2021 6:45 am GNW   Ultimovacs ASA Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma
11 Aug 2021 4:00 pm GNW   Ultimovacs ASA Ultimovacs ASA: Invitation to second quarter 2021 results webcast presentation
05 Aug 2021 7:00 am GNW   Ultimovacs ASA Ultimovacs announces first patient enrolled in Phase II FOCUS trial of UV1 in head-and-neck cancer
05 Jul 2021 8:30 pm GNW   Ultimovacs ASA Ultimovacs’ Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines
04 Jun 2021 2:00 pm GNW   Ultimovacs ASA Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program


Company Announcements Archive »


a d v e r t i s e m e n t